Skip to Main Content

Long-Term PF-06651600 for the Treatment of Alopecia Areata (ALLEGRO-LT)

Conditions

Immune System

Phase III

What is the purpose of this trial?

This is a global Phase 3 study to evaluate the safety and effectiveness of an investigational study drug (called PF-06651600) in adults and adolescents (12 years and older) who have alopecia areata. Eligible patients from the prior studies B7931005 (NCT02974868) and B7981015 (NCT03732807) will have an opportunity to enroll as well as patients who have not previously participated in either of these studies. The study is open-label and all patients entering the study will receive active study drug.

  • Trial with
    Pfizer Inc., U.S. Pharmaceuticals Group
  • Start Date
    02/27/2020
  • End Date
    04/30/2023
Trial Image

For more information about this study, contact:

Elizabeth Szymanski

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    04/22/2020
  • Study HIC
    #2000026562